The effects of the selective chymase inhibitor TEI-F00806 were examined on angiotensin I (Ang I)-induced hypertension and intrarenal angiotensin II (Ang II) production in salt-treated mice. Twelve-week-old C57BL male mice were given a high-salt diet (4% NaCl + saline (0.9% NaCl)), and divided into three groups: (1) sham + vehicle (5% acetic acid in saline), (2) Ang I
INTRODUCTION
The renin-angiotensin system (RAS) plays a critical role in the regulation of body fluid balance and blood pressure (Kobori, Nangaku, Navar, & Nishiyama, 2007; Navar, Mitchell, Harrison-Bernard, Kobori, & Nishiyama, 2001) . Previous studies have demonstrated that kidneys express all RAS components (Kobori et al., 2007) , while the inappropriate augmentation of intrarenal angiotensin II (Ang II) production contributes to the development of hypertension through c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society stimulating tubular sodium reabsorption (Gonzalez-Villalobos et al., 2011; Satou, Shao, & Navar, 2015) .
Angiotensin-converting enzyme (ACE) catalyses the conversion of angiotensin I (Ang I) to Ang II in the plasma, so ACE inhibitors are widely used for treating hypertension (Sparks, Crowley, Gurley, Mirotsou, & Coffman, 2014) . However, the chymotrypsin-like serine protease chymase also plays an important role in converting Ang I to Ang II in tissues (Miyazaki & Takai, 2000 Urata et al., 1993) . Chymase was originally found in the secretory granules of mast cells (Schick, Austen, & Schwartz, 1984) , but has since been detected in the heart, vasculature and kidneys (Miyake-Ogawa et al., 2005) . The conversion of Ang I to Ang II is predominantly mediated by chymase instead of ACE in several tissues, for example the vasculature, alimentary tract, skin, kidney and skeletal muscle (Devarajan et al., 2015; Le & Coffman, 2006; Park et al., 2013; Takai, Jin, & Miyazaki, 2012) . Moreover, the antihypertensive effects of ACE inhibitors in treating hypertension are not always sufficient because their ability to reduce renal Ang II production is limited (Fox, Guan, Hymel, & Navar, 1992; Maeda et al., 2010) . Indeed, chymase can produce Ang II even in the presence of ACE inhibitors (Wei et al., 2010) .
The exact antihypertensive effects of chymase inhibitors are still unclear. Previous studies have shown that salt-induced moderate hypertension was dose-dependently attenuated by a chymase inhibitor in mice (Devarajan et al., 2015) . In contrast, in type 1 diabetic hamsters, a chymase inhibitor improved diabetes-induced oxidative stress without affecting blood pressure . Similarly, in uninephrectomized rats with a high salt intake and Goldblatt renal artery stenosis (two-kidney one clip), the non-specific chymase inhibitor chymostatin decreased tissue Ang II levels without changing blood pressure (Roszkowska-Chojecka et al., 2015) . Therefore, the present study was conducted to test the hypothesis that chymase inhibition prevents Ang I-induced hypertension through inhibiting the conversion of Ang I to Ang II in the kidney. This was tested by examining the effects of the selective chymase inhibitor TEI-F00806 (Maeda et al., 2012; Welches, Brosnihan, & Ferrario, 1993) on Ang Iinduced hypertension and intrarenal Ang II production in salt-treated mice.
METHODS

Ethical approval
The experimental procedures were approved by the animal research committee of Kagawa University (approval number 15031). All 
Animals
Twelve-week-old male C57BL mice (Japan SLC, Inc., Shizuoka, Japan)
were housed in specific pathogen-free animal facilities at a controlled temperature (24 ± 2 • C) and humidity (55 ± 5%) on a 12 h light-dark cycle. All mice were given a free access to high-salt diet (4% NaCl) and 0.9% NaCl in drinking tap water, and divided into three groups 
Measurement of blood pressure
Blood pressure was measured using the non-invasive tail-cuff technique (Nishiyama et al., 2010) . Data were recorded at baseline and 7, 14, 21 and 28 days after minipump implantation. After allowing the animals to rest for at least 15 min, the systolic blood pressure was measured five consecutive times by a tail-cuff plethysmograph (model BP-98A; Softron Co., Tokyo, Japan). The lowest three values were averaged.
Measurement of chymase and ACE mRNA expression
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA), and first-strand cDNA was synthesized using the High Capacity 
Measurement of kidney Ang II
We measured Ang II levels in accordance with the methods established by Professor Navar's laboratory (Tulane University, New Orleans, LA, USA) (Nishiyama et al., 2004; Nishiyama, Seth, & Navar, 2002) . In brief, frozen kidney tissues were homogenized in 5 ml ice-cold methanol.
The homogenate was centrifuged at 1630 g for 15 min, and the supernatant was dried by heating at 85 • C for the complete and irreversible inactivation of renin. The residue was reconstituted in 1 ml Ang assay buffer (50 mM sodium phosphate, 1 mM EDTA, 0.25 mM thimerosal, 2.5 mg ml −1 bovine serum albumin, pH 7.4).
Ang II peptides were then extracted using phenyl-bonded, solid-phase extraction columns (Agilent Technologies Inc., Santa Clara, CA, USA).
The efficiency of Ang II recovery as determined by 125 I-radiolabelled
Ang II was about 80%. Eluates were vacuum-dried to remove methanol, reconstituted in 500 l Ang assay buffer and subjected to radioimmunoassay for Ang II.
Immunohistochemistry of angiotensinogen
Immunostaining of angiotensinogen (AGT) was performed using 15%
formalin-fixed paraffin-embedded whole kidney tissues. 
Western blotting of angiotensinogen
To determine AGT protein expression in the kidney, protein was collected from cortical tissues using lysis buffer (Cell Signaling 
Measurement of urine volume and urinary sodium excretion
At the end of the 28-day experimental period, mice were kept in a metabolic cage for 24-h urine collection. Urinary sodium was measured by an automated analyser (7020-Automatic Analyzer; Hitachi High
Technologies, Tokyo, Japan).
Statistical analysis
Data are presented as the mean ± SD. The statistical significance of differences in blood pressure was determined using two-way analysis of variance followed by the Bonferroni post hoc test. For comparisons of other data, one-way analysis of variance followed by Tukey's multiple comparison test was performed using Prism software v. 5.0
(GraphPad Software Inc., La Jolla, CA, USA). A P-value <0.05 was considered statistically significant.
RESULTS
General information
There were no significant differences in body weight among all three groups at baseline (sham + vehicle: 24 ± 1.0 g; Ang I + vehicle: 25 ± 1.0 g; Ang I + TEI-F0086: 24 ± 1.0 g) and after 4 weeks (sham + vehicle:
26 ± 1.0 g; Ang I + vehicle: 26 ± 1.7 g; Ang I + TEI-F0086: 25 ± 1.5 g).
TEI-F0086 significantly increased urine volume (10.3 ± 1.5 ml (24 h) −1 ) compared with sham + vehicle (5.4 ± 1.8 ml (24 h) −1 , P < 0.01) and Ang I + vehicle (6.8 ± 3.8 ml (24 h) −1 , P < 0.05). Water intake was also significantly increased in Ang I + vehicle (15.8 ± 4.1 ml (24 h) −1 )
and Ang I + TEI-F0086 groups (17.2 ± 2.1 ml (24 h) −1 ) compared with the sham + vehicle (12.4 ± 2.8 ml (24 h) −1 ) group (P < 0.01). TEI-F0086 also significantly increased urine sodium excretion (3.6 ± 0.4 mmol (24 h) −1 ) compared with Ang I + vehicle (2.5 ± 0.5 mmol (24 h) −1 , P < 0.05) (data not shown).
Effect of TEI-F00806 on blood pressure
As shown in Figure 1 , Ang I infusion resulted in the development of hypertension. The systolic blood pressure was significantly increased from 105 ± 5 mmHg at baseline to 149 ± 23 mmHg after 4 weeks (P < 0.001). TEI-F00606 treatment significantly lowered the systolic blood pressure to 113 ± 3 mmHg compared with the Ang I group at 4 weeks (P < 0.001). These data indicate that TEI-F00806 attenuated Ang I-induced hypertension.
Effect of TEI-F00806 on chymase and ACE expression
Chronic Ang I infusion significantly increased renal chymase expression (P < 0.05). However, chymase mRNA expression was not changed by Ang I infusion during treatment with TEI-F0086
( Figure 2 ). There were no significant differences in renal ACE mRNA expression among the groups. 
Effect of TEI-F00806 on kidney AGT
We analysed AGT expression in the kidney using both immunohistochemistry and western blotting. Immunohistochemical analysis showed that Ang I infusion significantly increased the intensity of AGT staining in the kidney (P < 0.001). However, treatment with TEI-F0086 prevented the Ang I-induced augmentation of AGT (Figure 4a) .
Similarly, as shown in Figure 4b , western blot analysis revealed significantly higher AGT protein levels in renal tissues of Ang I-induced hypertensive mice compared with sham (P < 0.01). Treatment with TEI-F0086 significantly decreased intrarenal AGT protein levels in Ang Iinfused mice (P < 0.05).
DISCUSSION
In this study, we tested the hypothesis that chymase inhibition prevents Ang I-induced hypertension by inhibiting the conversion of Ang I to Ang II in the kidney. For this purpose, we infused Ang I for 4 weeks in salt-treated mice and examined the effects of the selective chymase inhibitor TEI-F0086. Based on previous studies (Gonzalez-Villalobos et al., 2011), we infused Ang I at a dose of 1 g kg −1 min −1 to induce hypertension. Although Gonzalez-Villalobos et al. (GonzalezVillalobos et al., 2011) showed that blood pressure was increased from 1 week after Ang I infusion, our data showed that blood pressure was increased from 3 weeks after Ang I infusion. We have no good explanation regarding the differences in the time course of Ang Iinduced blood pressure elevation. However, this discrepancy may be due to differences in experimental conditions, such as variations in baseline blood pressure between the studies. Additionally, the previous study was performed in both male and female ACE 9/9 and wild-type littermates. The selective chymase inhibitor TEI-F0086 was shown to decrease the Ang II content in the kidney, which strongly supports our hypothesis that chymase inhibition reduces intrarenal Ang II levels thereby attenuating the development of hypertension.
Our data showed that chronic Ang I infusion significantly increased both renal Ang II levels and blood pressure in salt-treated C57BL mice. Humans and hamsters share a common -chymase that plays a predominant role in tissue Ang II generation (Akasu et al., 1998; Kinoshita, Urata, Bumpus, & Husain, 1991) , while mice and rats have 14 -chymase proteins that degrade Ang II (Gallwitz & Hellman, 2006; Maeda et al., 2010) . However, mice were used in the present study because of difficulties with blood pressure measurement in hamsters.
It was previously reported that local Ang II formation is dependent on both ACE and chymase (Kobori et al., 2007) . However, after treatment with high salt, chymase-dependent Ang II formation was obvious in several tissues (Devarajan et al., 2015) . Therefore, we examined the effects of a chymase inhibitor in salt-treated animals. Here, we showed that the chymase-specific inhibitor TEI-F0086 (Maeda et al., 2012; Welches et al., 1993) significantly inhibited the development of hypertension in Ang I-infused salt-treated mice. These data are in agreement with previous studies that showed chymase-dependent Ang II generation is associated with the development of hypertension in salt-treated mice (Devarajan et al., 2015) . In salt-dependent moderate hypertension in mice, ACE-dependent Ang II formation is not involved because the use of ACE inhibitors was shown not to alter blood pressure (Devarajan et al., 2015) . It is also important to note that chronic ACE inhibition increased the expression and activity of chymase in the heart (Wei et al., 2010) . Furthermore, chronic treatment with an ACE inhibitor failed to reduce Ang II levels in the kidneys of Ang I-infused rats (Ohnishi et al., 2013) and in isolated human arterial appendage tissues (Ahmad et al., 2011) . In the present study, we also found no increase in ACE mRNA levels in the renal tissues of salt-treated Ang I-infused hypertensive mice.
Chymase is activated upon release from mast cell granules; however, the number of mast cells is low in healthy kidneys (Takai et al., 2012; Wasse et al., 2012) . Chymase mRNA expression and activity were shown to be increased in cardiac and liver tissues of spontaneously hypertensive rats, and were positively correlated with the extent of mature mast cell infiltration in the renal tissue of primary hypertensive nephropathy patients (Guo et al., 2001; Liu et al., 2012; Miyaoka et al., 2017; Welker et al., 2008; Yamada et al., 2001) . Importantly, several studies have shown that chymase mRNA and chymase-like activity were increased in injured vascular tissue (Ju et al., 2001; Shiota et al., 1993; Shiota et al., 1999) .
In the present study, we observed increased chymase mRNA expression in renal tissues of Ang I-infused hypertensive mice, which was significantly suppressed by treatment with TEI-F0086. These data are in agreement with previous studies that reported the reduction of both chymase mRNA and activity by treatment with a chymase inhibitor in the skin (Shiota, Kakizoe, Shimoura, Tanaka, & Okunishi, 2005) , liver (Miyaoka et al., 2017) , and cardiac tissue (Kanemitsu et al., 2006; Matsumoto et al., 2003) , although the precise mechanism by which chymase inhibitors decrease chymase gene expression is not clear. Mast cells release several compounds such as histamine, leukotrienes, cytokines, chemokines and chymase upon degranulation (Amin, 2012) . Chymase gene expression was increased after the administration of a mast cell degranulation-mediating compound (Lindstedt et al., 2001) , and chymase can induce secretory granule secretion from rat serosal mast cells (Schick et al., 1984) . Additionally, chymase-specific inhibitors can act as mast cell stabilizers, thereby decreasing its activation in mice (Bot et al., 2011; He, Gaca, McEuen, & Walls, 1999) . Moreover, chymase inhibitors decrease the number of chymase-positive mast cells in the liver (Komeda et al., 2010) . However, further studies are needed to elucidate the underlying mechanism responsible for the effect of chymase inhibitors on chymase gene expression in the kidney.
In the present study, Ang I-infused mice showed increases in intrarenal angiotensinogen protein levels and Ang II contents. These findings are consistent with the concept that elevated intrarenal Ang II generation stimulates angiotensinogen expression in the kidney, which may lead to further increases in the local production of Ang II (Gonzalez-Villalobos et al., 2008; Kobori et al., 2007; Kobori, HarrisonBernard, & Navar, 2001a, b; Satou et al., 2015; Schunkert et al., 1992) . Previous studies have shown a positive correlation between the number of chymase-positive mast cells and Ang II-positive cells (Komeda et al., 2010) . Therefore, we speculate that intrarenal Ang II formation is reduced by specific chymase inhibition with TEI-F0086 during Ang I infusion. Intrarenal Ang II elevation is known to induce sodium retention and the development of hypertension (Kobori et al., 2007) . In the present study, blood pressure elevation was associated with a reduction in 24-h urinary sodium excretion in Ang I-infused mice. We also observed that the specific chymase inhibitor, TEI-F0086, significantly (P < 0.05) increased urinary sodium excretion, which is associated at least in part with reduced intrarenal Ang II production.
The biochemical and physiological role of chymase is speciesspecific (Akasu et al., 1998; Doggrell & Wanstall, 2004) . Mice havechymase, which degrades Ang II , while humans and hamsters both have the same chymase, -chymase (Hoshino et al., 2003; Ikemoto et al., 1986) , so hamsters are often used for chymase-related studies. A limitation of this study is that we examined the effects of a chymase inhibitor in mice, not hamsters. However, we were not able to measure blood pressure in hamsters using the tail-cuff method, while telemetry for hamsters is not commercially available.
In conclusion, our data support the hypothesis that intrarenal Ang II production and the development of hypertension are prevented by selective chymase inhibition in Ang I-infused hypertensive mice. Further studies are needed to elucidate the beneficial effects of selective chymase inhibitors in hypertensive patients. Guo, C., Ju, H., Leung, D., Massaeli, H., Shi, M., & Rabinovitch, M. (2001 
